In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Lucas Downey is the co-founder of MoneyFlows, and an Investopedia Academy instructor. Dr. JeFreda R. Brown is a financial consultant, Certified Financial Education Instructor, and researcher who has ...

Marshall Hargrave is a stock analyst and writer with 10+ years of experience covering stocks and markets, as well as analyzing and valuing companies. Michael Boyle is an experienced financial ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

This article, presented in the backdrop of the debates on the state of political theory in India, argues that the terms of debate need to shift to include the question of method of doing political ...

Summary In this episode of The Defenders Log, Paul Mockapetris, the architect of DNS, discusses the evolving role of the Domain Name System from a simple directory to a sophisticated security tool. He ...

The leaked internal chat communications of the Black Basta ransomware group offer an unprecedented view into how cybercriminals operate, plan attacks, and ...

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...